This trial is organized into 28-day cycles. Participants in this trial will be randomly assigned in to one of three different groups, or arms. Participants in all arms may receive pre-treatment medications to help minimize the risk of side effects from the study drugs.

Treatment Involved

The investigational medication being studied is a type of drug called a bispecific antibody. Bispecific antibodies are drugs that have two different targets. This investigational medication’s two targets are CD3, a receptor found on our own T cells, and GPRC5D, a protein found on the surface of some myeloma cells. The investigational medication is being evaluated to determine if once in the body, it will draw the body’s T cells and myeloma cells closer together, resulting in T cell activation and myeloma cell death.